Nickel-Catalyzed Synthesis of Benzocoumarins: Application to the Total Synthesis of Arnottin I

Sachin Madan and Chien-Hong Cheng*

Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan

chcheng@mx.nthu.edu.tw

Received July 17, 2006



The ring-opening addition of methyl 2,3-dimethoxy-6-iodobenzoate to oxabenzonorbornadienes followed by cyclization in the presence of NiBr₂(dppe) and Zn metal powder in acetonitrile at 80 °C to give the corresponding benzocoumarin derivatives is described. This methodology was then applied to the synthesis of natural product arnottin I, first isolated from *Xanthoxylum arnottianum* Maxim, using protecting group chemistry. After deprotection and subsequent ring closure, arnottin I was obtained in 21% overall yield after six steps starting from catechol.

Gilvocarcins¹ and other related compounds, such as ravidomycin² and chrysomycins,³ are metabolites of certain *Streptomyces* species and belong to a class of aryl C-glycoside antibiotics⁴ (Figure 1). These molecules, sharing a common tetracyclic aromatic nucleus, 6H-benzo[d]naphtho[1,2-b]pyran-6-one to which sugars are attached at the C-4 position, have attracted great attention. Defucogilvocarcins⁵ having a similar chromophore have also been extensively studied (Figure 1).

(4) For an excellent review on aryl C-glycoside antibiotics, see: Hacksell, U.; Daves, G. D., Jr. *Prog. Med. Chem.* **1985**, *22*, 1–65.



FIGURE 1. Structures of gilvocarcin-class antibiotics.

However, the coumarin-based natural product arnottin I, having a 6H-benzo[d]naphtho[1,2-b]pyran-6-one skeleton found in gilvocarcin-type antibiotics, has received less attention.⁶ Previously, it has been synthesized utilizing a 2-methylarenofuran as a masked salicylaldehyde^{6a} and also via the internal aryl-aryl coupling reaction of aryl *ortho*-halobenzoate catalyzed by palladium complexes.⁷

Our long and continued interest in nickel chemistry^{8,9} and the coumarin¹⁰ synthesis encouraged us to investigate a new

10.1021/jo061477h CCC: \$33.50 © 2006 American Chemical Society Published on Web 09/13/2006

⁽¹⁾ For isolation and structure elucidation of gilvocarcin V and M, see: (a) Horii, S.; Fukase, H.; Mizuta, E.; Hatano, K.; Mizuno, K. Chem. Pharm. Bull. **1980**, 28, 3601. (b) Nakano, H.; Matsuda, Y.; Ito, K.; Ohkubo, S.; Morimoto, M.; Tomita, F. J. Antibiot. **1981**, 34, 266. (c) Takahashi, K.; Yoshida, M.; Tomita, F.; Shirahata, K. J. Antibiot. **1981**, 34, 266. Mirayama, N.; Takahashi, K.; Shirahata, K. J. Antibiot. **1981**, 34, 266. (c) Takahashi, K.; Yoshida, M.; Tomita, F.; Shirahata, K. J. Antibiot. **1981**, 34, 266. (c) Takahashi, K.; Yoshida, M.; Tomita, F.; Shirahata, K. J. Antibiot. **1981**, 34, 266. (c) Takahashi, K.; Yoshida, M.; Tomita, F.; Shirahata, K. J. Antibiot. **1981**, 34, 266. (c) Takahashi, K.; Yoshida, M.; Tomita, F.; Shirahata, K. D. M.; O'Herron, F. A.; Bush, J.; Vyas, D. M.; Nettleton, D. E.; Grulich, R. E.; Bradner, W. T.; Doyle, T. W.; Arnold, E.; Clardy, J. J. Antibiot. **1981**, 34, 1544. (f) Jain, T. C.; Simolike, G. C.; Jackman, L. M. Tetrahedron **1983**, 39, 599. For the total synthesis of gilvocarcin V and M, see: (g) Matsumoto, T.; Hosoya, T.; Suzuki, K. J. Am. Chem. Soc. **1992**, 114, 3568. (h) Hosoya, T.; Takashiro, E.; Matsumoto, T.; Suzuki, K. J. Am. Chem. Soc. **1994**, 116, 1004.

⁽²⁾ For isolation and structure determination of ravidomycin, see: (a) Findlay, J. A.; Liu, J.-S.; Radics, L.; Rakhit, S. *Can. J. Chem.* **1981**, *59*, 3018. (b) Findlay, J. A.; Liu, J.-S.; Radics, L. *Can. J. Chem.* **1983**, *61*, 323. (c) Narita, T.; Matsumoto, M.; Mogi, K.; Kukita, K.; Kawahara, R.; Nakashima, T. J. Antibiot. **1989**, *42*, 347. For the total synthesis of ravidomycin, see: (d) Futagami, S.; Ohashi, Y.; Imura, K.; Ohmori, K.; Matsumoto, T.; Suzuki, K. *Tetrahedron Lett.* **2000**, *41*, 1063.

⁽³⁾ For chrysomycin A and B, see: (a) Strelitz, F.; Flon, H.; Asheshov, I. N. *J. Bacteriol.* **1955**, *69*, 280. (b) Weiss, U.; Yoshihira, K.; Highet, R. J.; White, R. J.; Wei, T. T. *J. Antibiot.* **1982**, *35*, 1194.

⁽⁵⁾ For isolation and structure of defucogilvocarcin V, see: (a) Misra, R.; Tritch, H. R., III; Pandey, R. C. J. Antibiot. 1985, 38, 1280. (b) Defucogilvocarcin M: Nakashima, T.; Fujii, T.; Sakai, K.; Sameshima, T.; Kumagai, H.; Yoshioka, T. PCT Patent Appl. W098/22612 A1, 1998; Chem. Abstr. 1998, 129, 49638. For the total synthesis of defucogilvocarcins, see: (c) Macdonald, S. J. F.; McKenzie, T. C.; Hassen, W. D. J. Chem. Soc., Chem. Commun. 1987, 1528. (d) Patten, A. D.; Nguyen, N. H.; Danishefsky, S. J. J. Org. Chem. 1988, 53, 1003. (e) Jung, M. E.; Jung, Y. H. Tetrahedron Lett. 1988, 59, 2517. (f) McGee, L. R.; Confalone, P. N. J. Org. Chem. 1988, 53, 3695. (g) Hart, D. J.; Merriman, G. H. Tetrahedron Lett. 1989, 30, 5093. (h) Deshpande, P. P.; Martin O. R. Tetrahedron Lett. 1990, 2931, 6313. (i) Parker, K. A.; Coburn, C. A. J. Org. Chem. 1991, 56, 1666. (j) Hua, D. H.; Saha, S.; Roche, D.; Maeng, J. C.; Iguchi, S.; Baldwin, C. J. Org. Chem. 1992, 57, 399. (k) Takemura, I.; Imura, K.; Matsumoto, T.; Suzuki, K. Org. Lett. 2004, 6, 2503.

⁽⁶⁾ For isolation and structure determination of arnottin I, see: (a) Ishii, H.; Ishikawa, T.; Murota, M.; Aoki, Y.; Harayama, T. *J. Chem. Soc., Perkin Trans. 1* **1993**, 1019. (b) Ishii, H.; Ishikawa, T.; Haginiwa, J. *Yakugaku Zasshi* **1977**, *97*, 890.

^{(7) (}a) Harayama, T.; Yasuda, H.; Akiyama, T.; Takeuchi, Y.; Abe, H. *Chem. Pharm. Bull.* **2000**, *48*, 861. (b) Harayama, T.; Yasuda, H. *Heterocycles* **1997**, *46*, 61.

^{(8) (}a) Rayabarapu, D. K.; Cheng, C.-H. J. Am. Chem. Soc. 2002, 124, 5630.
(b) Huang, Y.-C.; Majumdar, K. K.; Cheng, C.-H. J. Org. Chem. 2002, 67, 1682.
(c) Rayabarapu, D. K.; Cheng, C.-H. Chem. Commun. 2002, 942.
(d) Shanmugasundaram, M.; Wu, M.-S.; Cheng, C.-H. Org. Lett. 2001, 3, 4233.
(e) Hsiao, T.-Y.; Santhosh, K. C.; Liou, K.-F.; Cheng, C.-H. J. Am. Chem. Soc. 1998, 120, 12232.

method for the synthesis of arnottin I via a nickel-catalyzed ring-opening addition of substituted *o*-iodobenzoate to oxabenzonorbornadienes. To the best of our knowledge, no nickel-catalyzed synthesis of arnottin I has been reported in the literature. Herein, we report the results of this study.

Initially the reaction was tested using commercially available 7-oxabenzonorbornadiene **1** and methyl 2,3-dimethoxy-6-iodobenzoate¹¹ **2**. Under the standard reaction conditions,¹² that is, NiBr₂(dppe) [dppe = 1,2-bis(diphenylphosphino)ethane] and Zn powder in CH₃CN at 80 °C under N₂ atmosphere for 12 h, the desired annulated coumarin **3** was obtained in 75% isolated yield (eq 1). Similarly, treatment of 2,3-dimethoxy-7-oxabenzonorbornadiene **4** with *o*-iodobenzoate **2** gave tetramethoxysubstituted coumarin **5** in 68% isolated yield (eq 1). Starting material **4** was prepared from 4,5-dibromoveratrole and furan in the presence of *n*BuLi at -78 °C using Diels–Alder reaction, while **2** was synthesized from 2,3-dimethoxybenzoic acid and thallic trifluoroacetate (prepared in situ by refluxing Tl₂O₃ in CF₃COOH for 2 days).¹³



The above examples have successfully demonstrated the utility of this nickel-catalyzed reaction in the synthesis of highly functionalized benzocoumarin derivatives. We thus decided to extend this methodology further for preparation of the coumarinbased natural product arnottin I. As shown from retrosynthetic analysis in Scheme 1, two approaches were tested for its synthesis. Path a involved the reaction of 1,3-dioxolane-substituted oxabenzonorbornadiene 6 with o-iodobenzoate 2. Compound 6 can be prepared via the Diels-Alder reaction of furan and the benzyne generated from commercially available 1,2-dibromo-4,5-methylenedioxybenzene and "BuLi. Unfortunately, the reaction of 6 with 2 in the presence of NiBr₂(dppe) and Zn powder in CH₃CN failed to give the desired natural product in decent yield even after variation of temperature and change of solvent for the reaction. Different nickel catalyst systems, such as NiBr2-(dppe)/dppe/Zn, NiBr2(dppe)/Zn/Et3N, NiCl2(dppe)/Zn/Et3N, NiBr₂(dppb)/Zn/Et₃N, NiBr₂(dppp)/Zn/Et₃N, and Ni(COD)₂/ PPh₃, gave only a trace amount of the desired product arnottin

(12) Rayabarapu, D. K.; Shukla, P.; Cheng, C.-H. Org. Lett. 2003, 5, 4903.
(13) Taylor, E. C.; Kienzle, F.; Robey, R.; McKillop, A. J. Am. Chem. Soc. 1970, 92, 2175.

SCHEME 1. Retrosynthetic Analysis



I. Further, no desired product was observed when nickel complex systems, such as NiCl₂(PPh₃)₂/Zn/Et₃N, NiCl₂(PPh₃)₂/Zn, and NiCl₂(PPh₃)₂/PPh₃/Zn having PPh₃ as the monodentate ligand, were employed. Under these reaction conditions, major product for the reaction of oxabenzonorbornadiene **6** with *o*-iodobenzoate **2** is **7** instead of the expected product arnottin I. Compound **7** is likely from the facile dehydroxylation (-MOH) of reaction intermediate **8** due to the highly electronrich character of the 1,3-benzodioxolane group that can stabilize an α -carbon cation intermediate or transition state during the elimination of the MOH group in **8** to give **7** (Figure 2).



FIGURE 2. Structures of 7 and 8.

We then turned our attention to the alternative route (Scheme 1, path **b**). Using protecting group methodology, benzyl-, allyl-, and silyl-protected oxabenzonorbornadienes **9**–**11** were synthesized in three steps starting from catechol. Treatment of catechol with bromine in acetic acid gave 4,5-dibromocatechol in 90% yield.¹⁴ Protection of the free hydroxyl groups as benzyl-/allyl-substituted derivatives (NaH, THF, RX), followed by the Diels–Alder reaction of the benzynes generated (*ⁿ*BuLi, THF, –78 °C) with furan, gave the corresponding 2,3-dibenzyl-and 2,3-diallyl-7-oxabenzonorbornadienes **9** and **10** in 52 and 46% yields, respectively (Scheme 2). Similarly, *tert*-butyldimethylsilyl was used as the protecting group (TBDMSCI,

SCHEME 2. Preparation of Substituted Oxabenzonorbornadienes 9–11



^{(9) (}a) Rayabarapu, D. K.; Yang, C.-H.; Cheng, C.-H. J. Org. Chem.
2003, 68, 6726. (b) Rayabarapu, D. K.; Cheng, C.-H. Chem.—Eur. J. 2003, 9, 3164. (c) Rayabarapu, D. K.; Chiou, C.-F.; Cheng, C.-H. Org. Lett. 2002, 4, 1679. (d) Huang, D.-J.; Rayabarapu, D. K.; Li, L.-P.; Sambaiah, T.; Cheng, C.-H. Chem.—Eur. J. 2000, 6, 3706. (e) Sambaiah, T.; Huang, D.-J.; Cheng, C.-H. New J. Chem. 1998, 22, 1147. (f) Shukla, P.; Cheng, C.-H. Org. Lett. 2006, 8, 2867.

^{(10) (}a) Murray, R. D. H.; Mendez, J.; Brown, S. A. *The Natural Coumarins: Occurrence, Chemistry, and Biochemistry*; Wiley: New York, 1982. (b) Naser-Hijazi, B.; Stolze, B.; Zanker, K. S. *Second Proceedings of the International Society of Coumarin Investigators*; Springer: Berlin, 1994. (c) Hepworth, J. D. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R., Rees, C. W., Boulton, A. J., McKillop, A., Eds.; Pergamon Press: Oxford, 1984; Vol. 3, Chapter 2.24, pp 799–810. (d) Staunton, J. In *Comprehensive Heterocyclic Chemistry*; Barton, D. H. R., Ollis, W. D., Sammes, P. G., Eds.; Pergamon Press: Oxford, 1979; Vol. 4, Chapter 18.2, pp 651–653.

⁽¹¹⁾ Dyke, S. F.; Tiley, E. P. Tetrahedron 1975, 31, 561.

SCHEME 3. Synthesis of Dihydroxy Coumarin 15



SCHEME 4. Total Synthesis of Arnottin I



imidazole, DMF) for the free hydroxyl groups in 4,5-dibromocatechol to prepare 1,2-bis(*tert*-butyldimethylsilyloxy)-4,5dibromobenzene. The Diels—Alder reaction of the corresponding benzyne generated (*"*BuLi, THF, -78 °C) with furan then afforded 1,2-bis(*tert*-butyldimethylsilyloxy)-7-oxabenzonorbornadiene **11** in 44% yield over three steps (Scheme 2).

With substituted oxabenzonorbornadienes 9-11 in hand, we carried out the nickel-catalyzed coumarin synthesis reaction. Hence, treatment of dibenzyl derivative 9 with *o*-iodobenzoate 2 under our standard reaction conditions furnished dibenzyl coumarin 12 in 65% isolated yield (Scheme 3). Debenzylation using H₂/Pd-C gave the desired dihydroxy compound 15 but only in 25% yield. Next, we used diallyl-substituted oxabenzonorbornadiene 10 as the substrate for reaction with 2 using our standard protocol to furnish diallyl coumarin 13 in 69% yield (Scheme 3). Deallylation with Pd(PPh₃)₄/morpholine^{15a} in degassed THF gave only a trace amount of dihydroxy derivative 15. Even Corey's modified Pd-catalyzed conditions^{15b} failed to give 15 in decent yield.

Finally, TBDMS-protected oxabenzonorbornadiene **11** was employed as substrate for the reaction with *o*-iodobenzoate **2** to give the corresponding coumarin derivative **14** in 72% isolated yield. The silyl groups were successfully removed by KF (10.0 equiv) in a mixture of THF and CH₃CN (1:1 by volume) to give dihydroxy derivative **15** in 90% yield. Final ring closure was carried out using triethylamine and CH₂Br₂ in CH₃CN under reflux for 15 h to furnish the title compound arnottin I **16** in 74% isolated yield (Scheme 4). The spectroscopic data of this compound are consistent with those reported previously.^{6a}

In summary, we have successfully demonstrated the use of the nickel-catalyzed ring-opening addition reaction of methyl 2,3-dimethoxy-6-iodobenzoate **2** to substituted oxabenzonorbornadienes to give highly functionalized benzocoumarin derivatives in good yields. The methodology was further extended to the preparation of natural product arnottin I employing TBDMSprotected oxabenzonorbornadiene **11** as the substrate for reaction with **2**. After removal of the TBDMS group under mild reaction conditions and subsequent ring closure, the desired compound arnottin I **16** was obtained in 21% overall yield after six steps.

Experimental Section

4,5-Dibromocatechol and 1,2-bis(benzyloxy)-4,5-dibromobenzene were prepared according to the methods reported in the literature.^{14,16,17}

General Procedure for the Preparation of Benzocoumarins 3 and 5. A round-bottom sidearm flask (25 mL) containing the corresponding bicyclic olefin 1 or 4 (1.5 mmol), methyl *o*-iodobenzoate 2 (1.0 mmol), NiBr₂(dppe) (31 mg, 0.05 mmol, 5 mol %), and Zn metal powder (2.75 mmol) was evacuated and purged with nitrogen gas four times. Freshly distilled CH₃CN (3.0 mL) was added to the above mixture, and the reaction mixture was stirred at 80 °C for 12 h. The reaction mixture was then cooled, diluted with methylene chloride (15 mL), and stirred in the air for 15 min. Then it was filtered through a short pad of Celite and silica gel. It was then washed with CH₂Cl₂ several times. The filtrate was concentrated in vacuo, and the crude product was purified by silica gel column using a mixture of ethyl acetate and hexanes as eluent to afford the corresponding benzocoumarin products 3 and 5.

7,8-Dimethoxy-6H-dibenzo[*c*,*h*]**chromene-6-one (3):** This compound was obtained in 75% yield; ¹H NMR (600 MHz, CDCl₃) δ 3.93 (s, 3H), 3.99 (s, 3H), 7.37 (d, 1H, *J* = 8.8 Hz), 7.51 (t, 1H), 7.54 (t, 1H), 7.63 (d, 1H, *J* = 8.8 Hz), 7.77 (d, 1H, *J* = 8.0 Hz), 7.83 (d, 1H, *J* = 8.8 Hz), 7.88 (d, 1H, *J* = 8.8 Hz), 8.48 (d, 1H, *J* = 8.2 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 56.4, 61.6, 112.7, 115.6, 118.0, 119.1, 119.4, 122.1, 123.6, 124.1, 126.9, 127.4, 127.5, 129.3, 133.6, 146.1, 151.6, 153.3, 157.6; HRMS calcd for C₁₉H₁₄O₄ 306.0892, found 306.0891.

2,3,7,8-Tetramethoxy-6*H***-dibenzo[***c***,***h***]chromene-6-one (5):** This compound was obtained in 68% yield; ¹H NMR (600 MHz, CDCl₃) δ 3.96 (s, 3H), 4.00 (s, 3H), 4.01 (s, 3H), 4.08 (s, 3H), 7.11 (s, 1H), 7.41 (d, 1H, J = 8.8 Hz), 7.53 (d, 1H, J = 8.7 Hz), 7.75

⁽¹⁴⁾ Kohn, M. J. Am. Chem. Soc. 1951, 73, 480.

 ^{(15) (}a) Eicher, T.; Ott, M.; Speicher, A. Synthesis 1996, 755. (b) Stoltz,
 B. M.; Kano, T.; Corey, E. J. J. Am. Chem. Soc. 2000, 122, 9044.

(s, 1H), 7.81 (d, 1H, J = 8.7 Hz), 7.85 (d, 1H, J = 8.8 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 55.9, 56.4, 56.5, 61.6, 101.0, 106.4, 111.7, 115.3, 117.5, 117.8, 118.8, 119.7, 122.6, 129.8, 129.9, 145.6, 150.2, 150.6, 151.7, 153.0, 157.9; HRMS calcd for C₂₁H₁₈O₆ 366.1103, found 366.1105.

General Procedure for the Preparation of Oxabenzonorbornadienes (6, 9–11). To a solution of appropriate dibromo compound (4.0 mmol) and furan (3 mL) in dry THF (25 mL) at -78 °C under N₂ atmosphere was added "BuLi (4.4 mmol, 2.5 M in hexanes) over a period of 1 h using a syringe pump. After the addition was completed, the reaction mixture was allowed to attain room temperature and was stirred overnight. It was quenched with brine and extracted with diethyl ether (4 × 10 mL). The combined organic layers were washed with brine and dried over MgSO₄. After concentration, the crude product was purified by silica gel chromatography using a mixture of ethyl acetate and hexanes as eluent to afford the corresponding substituted 7-oxabenzonorbornadienes (6, 9–11).

2,3-Methylenedioxy-7-oxabenzonorbornadiene (6):¹⁸ This compound was obtained in 45% yield; ¹H NMR (600 MHz, CDCl₃) δ 5.62 (s, 2H), 5.87 (s, 1H), 5.92 (s, 1H), 6.82 (s, 2H), 7.02 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 82.4, 101.1, 103.8, 143.2, 143.3, 144.3; HRMS calcd for C₁₁H₈O₃ 188.0473, found 188.0475.

2,3-Bis(benzyloxy)-7-oxabenzonorbornadiene (9): This compound was obtained in 52% yield; ¹H NMR (600 MHz, CDCl₃) δ 5.09 (s, 4H), 5.62 (s, 2H), 6.98 (s, 2H), 6.99 (s, 2H), 7.26–7.42 (m, 10H); ¹³C NMR (150 MHz, CDCl₃) δ 72.3, 82.4, 110.7, 127.8, 128.0, 128.4, 137.4, 142.6, 143.1, 146.0; HRMS calcd for C₂₄H₂₀O₃ 356.1412, found 356.1414.

2,3-Bis(allyloxy)-7-oxabenzonorbornadiene (**10**): This compound was obtained in 46% yield; ¹H NMR (500 MHz, CDCl₃) δ 4.53 (d, 4H, J = 5.0 Hz), 5.22 (dd, 2H, J = 1.5 and 10.5 Hz), 5.36 (dd, 2H, J = 1.5 and 17.0 Hz), 5.62 (s, 2H), 6.03 (m, 2H), 6.94 (s, 2H), 6.99 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 70.8, 82.4, 109.9, 117.4, 133.6, 142.1, 143.1, 145.5; HRMS calcd for C₁₆H₁₆O₃ 256.1099, found 256.1102.

2,3-Bis(*t*-butyldimethylsilyloxy)-7-oxabenzonorbornadiene (11): This compound was obtained in 57% yield; ¹H NMR (600 MHz, CDCl₃) δ 0.16 (s, 6H), 0.17 (s, 6H), 0.97 (s, 18H), 5.59 (s, 2H), 6.78 (s, 2H), 6.95 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ -4.1 (CH₃-Si), -4.1 (CH₃-Si), 18.3, 25.9, 82.3, 114.9, 141.5, 142.8, 142.9; HRMS calcd for C₂₂H₃₆O₃Si₂ 404.2203, found 404.2205.

Methyl 2,3-dimethoxy-6-(naphtho[2,3-d][1,3]dioxol-7-yl)benzoate (7). A round-bottom sidearm flask (25 mL) containing 6 (280 mg, 1.5 mmol), o-iodobenzoate 2 (320 mg, 1.0 mmol), NiBr₂(dppe) (31 mg, 0.05 mmol, 5 mol %), and Zn metal powder (2.75 mmol) was evacuated and purged with nitrogen gas four times. Freshly distilled CH₃CN (3.0 mL) was added to the above mixture, and the reaction mixture was stirred at 80 °C for 12 h. The reaction mixture was then cooled, diluted with methylene chloride (15 mL), and stirred in air for 15 min. Then it was filtered through a short pad of Celite silica gel and washed with CH₂Cl₂ several times. After concentration in vacuo, the crude product was purified by silica gel column (ethyl acetate: hexanes, 1:15) to afford 265 mg of the title compound 7 in 73% yield: ¹H NMR (600 MHz, CDCl₃) δ 3.63 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 6.02 (s, 2H), 7.01 (d, 1H, J = 8.5 Hz), 7.09 (s, 1H), 7.10 (s, 1H), 7.16 (d, 1H, J = 8.5 Hz), 7.32 (dd, 1H, J = 1.8 and 8.3 Hz), 7.62 (s, 1H), 7.63 (d, 1H, J =8.5 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 52.3, 56.0, 61.7, 101.0, 103.6, 104.0, 113.4, 124.8, 125.6, 126.1, 127.0, 128.8, 129.4, 130.3, 132.4, 135.6, 146.0, 147.6, 147.8, 151.7, 168.2; HRMS calcd for C₂₁H₁₈O₆ 366.1103, found 366.1104.

General Procedure for the Preparation of Dibenzocoumarins 12–14. These compounds were prepared according to the procedure already reported above for compounds **3** and **5**.

2,3-Bis(benzyloxy)-7,8-dimethoxy-6*H***-dibenzo[***c***,***h***]chromene-6-one (12):** This compound was obtained in 65% yield; ¹H NMR (600 MHz, CDCl₃) δ 3.92 (s, 3H), 4.02 (s, 3H), 5.24 (s, 2H), 5.31 (s, 2H), 7.14 (s, 1H), 7.28–7.57 (m, 12H), 7.68–7.73 (m, 2H), 7.85 (s, 1H); ¹³C NMR (150 MHz, CDCl₃) δ 56.6, 61.5, 70.9, 71.0, 103.6, 109.4, 111.7, 115.4, 117.5, 117.6, 119.1, 119.9, 122.6, 126.4, 127.1, 127.2, 127.4, 127.8, 127.8, 128.5, 130.0, 130.0, 136.9, 145.6, 150.0, 150.3, 151.9, 153.0, 157.7; HRMS calcd for C₃₃H₂₆O₆ 518.1729, found 518.1730.

2,3-Bis(allyloxy)-7,8-dimethoxy-6H-dibenzo[*c,h*]**chromene-6one (13):** This compound was obtained in 69% yield; ¹H NMR (600 MHz, CDCl₃) δ 3.95 (s, 3H), 4.01 (s, 3H), 4.71 (d, 2H, *J* = 5.2 Hz), 4.78 (d, 2H, *J* = 5.2 Hz), 5.33 (m, 2H), 5.51 (m, 2H), 6.16 (m, 2H), 7.10 (s, 1H), 7.38 (d, 1H, *J* = 8.8 Hz), 7.48 (d, 1H, *J* = 8.7 Hz), 7.75 (s, 1H), 7.76 (d, 1H, *J* = 8.8 Hz), 7.81 (d, 1H, *J* = 8.9 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 56.5, 61.5, 69.5, 69.7, 102.5, 108.2, 111.6, 115.2, 117.4, 117.7, 118.0, 118.1, 118.8, 119.6, 122.6, 129.7, 129.9, 132.7, 132.8, 145.5, 149.4, 149.7, 151.6, 152.9, 157.8; HRMS calcd for C₂₅H₂₂O₆ 418.1416, found 418.1418.

2,3-Bis(*t*-butyldimethylsilyloxy)-7,8-dimethoxy-6*H*-dibenzo-[*c*,*h*]chromene-6-one (14): This compound was obtained in 72% yield; ¹H NMR (600 MHz, CDCl₃) δ 0.28 (s, 6H), 0.30 (s, 6H), 1.02 (s, 9H), 1.03 (s, 2H), 3.91 (s, 3H), 3.99 (s, 3H), 7.16 (s, 1H), 7.33 (d, 1H, *J* = 8.8 Hz), 7.43 (d, 1H, *J* = 8.8 Hz), 7.70 (d, 1H, *J* = 8.7 Hz), 7.76 (d, 1H, *J* = 8.7 Hz), 7.84 (s, 1H); ¹³C NMR (150 MHz, CDCl₃) δ -4.1 (-CH₃-Si), -4.1 (-CH₃-Si), 18.5, 18.5, 25.9, 26.0, 56.4, 61.4, 110.7, 111.3, 115.3, 116.2, 117.3, 117.6, 119.4, 122.4, 129.8, 130.2, 145.3, 148.4, 148.9, 151.5, 152.8, 157.7; HRMS calcd for C₃₁H₄₂O₆Si₂ 566.2520, found 566.2524.

2,3-Dihydroxy-7,8-dimethoxy-6*H***-dibenzo[***c***,***h***]chromene-6one (15): To a solution of 14 (400 mg, 0.70 mmol) in THF:CH₃-CN (1:1, 8 mL) was added KF (406 mg, 7 mmol), and the reaction mixture was stirred at room temperature for 15 h. The solid formed in the reaction mixture was separated and washed several times with diethyl ether. It was then dried under vacuum overnight to furnish 215 mg of 15 (90%): ¹H NMR (500 MHz, CD₃CN) \delta 3.78 (s, 3H), 3.85 (s, 3H), 6.82 (s, 1H), 7.19 (s, 1H); 7.31 (d, 1H,** *J* **= 8.8 Hz), 7.59 (d, 1H,** *J* **= 9.0 Hz), 7.65 (d, 1H,** *J* **= 8.9 Hz), 7.97 (d, 1H,** *J* **= 9.0 Hz); ¹³C NMR (150 MHz, CD₃CN) \delta 56.9, 61.5, 100.8, 108.1, 109.1, 114.2, 115.2, 116.9, 118.7, 121.4, 122.6, 130.3, 130.8, 145.0, 150.9, 152.5, 153.8, 155.4, 158.4.**

Preparation of Arnottin I (16). A mixture of **15** (200 mg, 0.60 mmol), methylene bromide (156 mg, 0.06 mL, 0.9 mmol), and triethylamine (180 mg, 0.25 mL, 1.8 mmol) in CH₃CN (10 mL) was refluxed for 15 h. After removal of the solvent, the residue was redissolved in CH₂Cl₂ (20 mL), washed with water and brine, and dried over MgSO₄. Column chromatographic purification (ethyl acetate:hexanes, 1:5) gave 150 mg of the desired natural product **16** (74%): ¹H NMR (600 MHz, CDCl₃) δ 3.97 (s, 3H), 4.01 (s, 3H), 6.08 (s, 2H), 7.11 (s, 1H), 7.42 (d, 1H, *J* = 8.4 Hz), 7.51 (d, 1H, *J* = 9.0 Hz), 7.81 (d, 1H, *J* = 9.0 Hz), 7.83 (s, 1H), 7.87 (d, 1H, *J* = 9.0 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 56.6, 61.6, 99.1, 101.5, 104.0, 111.7, 117.7, 117.8, 119.7, 120.0, 123.2, 125.0, 129.8, 131.2, 135.2, 144.0, 145.4, 148.2, 151.8, 153.1, 157.7; HRMS calcd for C₂₀H₁₄O₆ 350.0790, found 350.0791.

Acknowledgment. The authors thank the National Science Council of the Republic of China (NSC 93-2811-M-007-039) for the financial support of this research.

Supporting Information Available: Copies of ¹H NMR spectra for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

```
JO061477H
```

⁽¹⁶⁾ Hu, M.; Brasseur, N.; Yildiz, S. Z.; van Lier, J. E.; Leznoff, C. C. J. Med. Chem. 1998, 41, 1789.

⁽¹⁷⁾ Stringer, M. B.; Wege, D. Tetrahedron Lett. 1980, 21, 3831.

⁽¹⁸⁾ Rayabarapu, D. K.; Sambaiah, T.; Cheng, C.-H. Angew. Chem., Int. Ed. 2001, 40, 1286.